Anticancer therapy

Xem 1-13 trên 13 kết quả Anticancer therapy
  • The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted ther-apeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor,

    pdf7p mobifone23 18-01-2013 24 2   Download

  • It has been said that the control of disease has three goals, which, in increasing order of attraction are palliation, cure, and prevention. For most types of disseminated cancer, medical science has achieved only the first of these objectives, while for some malignancies the side effects of the therapeutic agents employed rival the disease itself in precluding a desirable quality of life.

    pdf423p tom_123 15-11-2012 23 4   Download

  • Abstract Resistance to conventional anticancer therapies in patients with advanced solid tumors has prompted the need of alternative cancer therapies. Moreover, the success of novel cancer therapies depends on their selectivity for cancer cells with limited toxicity to normal tissues. Several decades after Coley's work a variety of natural and genetically modified non-pathogenic bacterial species are being explored as potential antitumor agents, either to provide direct tumoricidal effects or to deliver tumoricidal molecules.

    pdf9p toshiba23 18-11-2011 32 2   Download

  • It is my privilege to introduce this Handbook on Advanced Cancer Care, which belongs to a series of publications initiated by the European Society for Medical Oncology (ESMO). There is a great need, especially for medical oncologists, to have a comprehensive overview of the essential elements needed for the care of patients with advanced cancer. This handbook fulfills these requirements. The Handbook on Advanced Cancer Care provides useful definitions and surveys of treatment principles.

    pdf290p tom_123 15-11-2012 51 11   Download

  • The collected Chapters in this volume describe the current status of poly(ethylene glycol) (PEG) modification of proteins, peptides, oligonucleotides and small molecule drugs, the recent advances in conjugation chemistry, and new clinical products. The book provides an excellent update in this rapidly evolving field, and the comprehensive collection of Chapters complements well past reviews/volumes that have documented the evolution of PEGylation. For example, a reader new to this field is encouraged to gain the historical perspective by reading the following reviews [1–8].

    pdf299p hyperion75 18-01-2013 21 5   Download

  • Solid tumours are complex structures in which the interdependent relation-ship between tumour and endothelial cells modulates tumour development and metastasis dissemination. The tumour microenvironment plays an important role in this cell interplay, and changes in its features have a major impact on tumour growth as well as on anticancer therapy respon-siveness.

    pdf12p galaxyss3 07-03-2013 15 2   Download

  • Both microtubule destabilizer and stabilizer agents are important molecules in anticancer therapy. In particular, paclitaxel has been demonstrated to be effective for the treatment of ovarian, breast, and nonsmall cell lung carci-nomas. It has been shown that emergence of resistance against this agent correlates with an increase in the relative abundance of tubulin isoform bIII and that the more recently discovered IDN5390 can be effectively used once resistance has emerged.

    pdf10p inspiron33 25-03-2013 16 2   Download

  • The spontaneous acquisition of resistance to a variety of unrelated cytotoxic compounds has important implications in medical treatment of infectious diseases and anticancer therapy. In the yeast Saccharomyces cerevisiaethis pheno-menon is caused by overexpression of membrane efflux pumps and is called pleiotropic drug resistance. We have found that allelic forms of the genes for the transcription activators Pdr1p and Pdr3p, designated PDR1-12and PDR3-33,respectively, mediate resistance to diazaborine....

    pdf8p dell39 03-04-2013 17 2   Download

  • With parallel breakthroughs occurring in molecular biology and nanoscience/technology, the newly recognized research thrust on “nanomedicine” is expected to have a revolutionary impact on the future of healthcare. To advance nanotechnology research for cancer prevention, diagnosis, and treatment, the United States National Cancer Institute (NCI) established the Alliance for Nanotechnology in Cancer in September 2004 and has pledged $144.3 million in the next five years (for details, visit

    pdf0p thuytienvang_1 31-10-2012 31 1   Download

  • Pyrimidine biosynthesis enzymes function in many cellular processes and are closely associated with pyrimidine antagonists used in cancer chemo-therapy. These enzymes are well characterized from bacteria to mammals, but not in a simple metazoan. To study the pyrimidine biosynthesis path-way inCaenorhabditis elegans, we screened for mutants exhibiting resis-tance to the anticancer drug 5-fluorouracil (5-FU).

    pdf12p vinaphone15 25-02-2013 18 1   Download

  • Hexadecylphosphocholine (HePC) is a synthetic lipid rep-resentative of a new group of antiproliferative agents, alkylphosphocholines (APC), which are promising candi-dates in anticancer therapy. Thus we have studied the action of HePC on the human hepatoblastoma cell line HepG2, which is frequently used as a model for studies into hepatic lipid metabolism.

    pdf7p research12 23-04-2013 13 1   Download

  • The ultimate goal of cancer research is the development of effective anticancer therapy. During the last several decades, the discovery of oncogenes, tumor suppressors, growth factors, signal transduction pathways has dramatically escalated our understanding of cancer cell biology and mechanisms of cell transformation.1-3 Hundreds of cellular proteins and pathways have been logically considered as molecular targets in a mechanism-based approaches of anticancer drug development.4-6 Yet, the progress in cancer treatment has not paralleled these dramatic achievements in basic research.

    pdf267p tom_123 15-11-2012 19 0   Download

  • Imidazolium trans-imidazoledimethyl sulfoxide-tetrachlo-roruthenate (NAMI-A) is a novel ruthenium-containing experimental antimetastatic agent. Compelling evidence ascribes apivotal role toendothelial cells in theorchestration of tumor angiogenesis and metastatic growth, suggesting antiangiogenic therapy as an attractive approach for anticancer treatment.

    pdf10p tumor12 22-04-2013 14 1   Download


Đồng bộ tài khoản